Enasidenib not checked
Celgene · AG-221 · AG-221 mesylate
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Isocitrate Dehydrogenase 2 Inhibitor FDA class
- Tested for
- Leukemia, Myeloid, Acute
- Main trialPhase 1/2
- “The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.”In the company’s words, NCT02677922 on ClinicalTrials.gov
- Other names
- AG-221 · IDHIFA · AG-221 mesylate · AGI-12910 · AGI-12910 mesylate · CC-90007
Other drugs for Leukemia, Myeloid, Acute
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 2 Aug 2018 | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | |
| Phase 3Completed | 17 Mar 2020 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation | |
| Phase 1/2Completed | 3 Jun 2016 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | |
| Phase 1/2Completed | 25 Jul 2019 | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | |
| Phase 1Completed | 8 Mar 2023 | Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment | |
| Phase 1Completed | 22 Sep 2023 | A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients | |
| Phase 3Authorised | not given | HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy. | |
| Phase 2Authorised | not given | IDEAL STUDY - A single-arm phase II multicenter study of IDH2 (AG-221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome | |
| Phase 1/2Authorised | not given | AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026